Regulatory approval

Published by the European Medicines Agency. Approved

The European Medicines Agency (EMA) has authorized atezolizumab for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) after chemotherapy. Patients with EGFR mutant or ALK-positive NSCLC should also have received targeted therapies before receiving atezolizumab.

This is written in the approval document as:

Tecentriq as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic NSCLC after prior chemotherapy. Patients with EGFR mutant or ALK-positive NSCLC should also have received targeted therapies before receiving Tecentriq.

Citation

Roche Registration GmbH. Tecentriq (atezolizumab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/tecentriq-epar-product-information_en.pdf. Revised March 2024. Accessed March 23, 2024.

Therapeutic response

Precision oncology relationships for therapeutic response derived from this regulatory approval.

Organizations	Biomarkers	Cancer types	Therapies
EMA (1)	EGFR Somatic variants	Non-Small Cell Lung Cancer	Atezolizumab
EMA (1)	v::ALK	Non-Small Cell Lung Cancer	Atezolizumab

Contributions

Date	Contributor	Description
2024-10-20	Van Allen lab	Adding EMA approvals for use to database
2017-09-20	European Medicines Agency	Indication received approval from the European Commission.